<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2026-03-25</startDate>
            <endDate>2026-03-25</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-25</startDate>
            <endDate>2026-03-25</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-16">0001372514</dei:EntityCentralIndexKey>
    <ffd:FormTp contextRef="c-1" id="f-17">S-8</ffd:FormTp>
    <ffd:SubmissnTp contextRef="c-1" id="f-18">S-8</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="c-1" id="f-19">EX-FILING FEES</ffd:FeeExhibitTp>
    <ffd:OffsetTableNa contextRef="c-1" id="f-20">N/A</ffd:OffsetTableNa>
    <dei:EntityRegistrantName contextRef="c-1" id="f-1">KIORA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="c-2" id="f-2">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c-2" id="f-3">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c-2" id="f-4">Common Stock, par value $0.01 per share(2)(3)(4)</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="c-2" id="f-5">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd contextRef="c-2" decimals="0" id="f-6" unitRef="shares">150469</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty contextRef="c-2" decimals="4" id="f-7" unitRef="usd">2.0625</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric contextRef="c-2" decimals="2" id="f-8" unitRef="usd">310342.31</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate contextRef="c-2" decimals="8" id="f-9" unitRef="number">0.00013810</ffd:FeeRate>
    <ffd:FeeAmt contextRef="c-2" decimals="2" id="f-10" unitRef="usd">42.86</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="c-1" decimals="2" id="f-11" unitRef="usd">310342.31</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="c-1" decimals="2" id="f-12" unitRef="usd">42.86</ffd:TtlFeeAmt>
    <ffd:TtlOffsetAmt contextRef="c-1" decimals="2" id="f-13" unitRef="usd">0</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="c-1" decimals="2" id="f-14" unitRef="usd">42.86</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c-2" id="f-15">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), this registration statement on Form S-8 (the &#x201c;Registration Statement&#x201d;) shall also cover any additional shares of the common stock, $0.01 par value per share (the &#x201c;Common Stock&#x201d;), of Kiora Pharmaceuticals, Inc. (the &#x201c;Registrant&#x201d;) that become issuable with respect to the securities identified in the above table, by reason of any stock dividend, stock splits, reverse stock splits, recapitalizations, reclassifications, mergers, split-ups, reorganizations, consolidations and other capital adjustments effected without receipt of consideration that increases the number of outstanding shares of Common Stock.&lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Represents (i) an increase of 150,469 shares of Common Stock that became reserved for issuance under the 2024 Plan as a result of the operation of the &#x201c;evergreen&#x201d; provision of the 2024 Plan, which provides that the total number of shares subject to such plan will be increased on January 1 of each year by a number of shares of common stock equal to 4% of the shares of common stock outstanding on December 31 of the immediately prior year, or such lesser number as determined by the Registrant&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act on the basis of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.0625, the average of the high and low prices of a share of Common Stock as reported on The Nasdaq Stock Market LLC on March 23, 2026.&lt;/span&gt;&lt;/div&gt;</ffd:OfferingNote>
</xbrl>
